GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (STU:JSS) » Definitions » Cyclically Adjusted Book per Share

Nxera Pharma Co (STU:JSS) Cyclically Adjusted Book per Share : €3.42 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted book value per share for the three months ended in Mar. 2024 was €4.523. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.42 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted Book Growth Rate was 13.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nxera Pharma Co was 15.60% per year. The lowest was 13.90% per year. And the median was 13.90% per year.

As of today (2024-06-14), Nxera Pharma Co's current stock price is €8.95. Nxera Pharma Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.42. Nxera Pharma Co's Cyclically Adjusted PB Ratio of today is 2.62.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nxera Pharma Co was 11.09. The lowest was 2.31. And the median was 4.58.


Nxera Pharma Co Cyclically Adjusted Book per Share Historical Data

The historical data trend for Nxera Pharma Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Cyclically Adjusted Book per Share Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.72 2.85 3.18 3.46 3.56

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.47 3.29 3.41 3.56 3.42

Competitive Comparison of Nxera Pharma Co's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PB Ratio falls into.



Nxera Pharma Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.523/107.2000*107.2000
=4.523

Current CPI (Mar. 2024) = 107.2000.

Nxera Pharma Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.864 98.000 2.039
201409 1.909 98.500 2.078
201412 1.857 97.900 2.033
201503 2.034 97.900 2.227
201506 2.107 98.400 2.295
201509 2.622 98.500 2.854
201512 3.329 98.100 3.638
201603 2.729 97.900 2.988
201606 3.656 98.100 3.995
201609 3.539 98.000 3.871
201612 3.675 98.400 4.004
201703 3.470 98.100 3.792
201706 3.605 98.500 3.923
201709 3.467 98.800 3.762
201712 4.972 99.400 5.362
201803 4.905 99.200 5.301
201806 4.741 99.200 5.123
201809 4.571 99.900 4.905
201812 0.000 99.700 0.000
201903 4.549 99.700 4.891
201906 4.441 99.800 4.770
201909 4.652 100.100 4.982
201912 4.824 100.500 5.146
202003 4.602 100.300 4.919
202006 4.373 99.900 4.693
202009 4.812 99.900 5.164
202012 5.147 99.300 5.556
202103 5.260 99.900 5.644
202106 5.164 99.500 5.564
202109 5.090 100.100 5.451
202112 5.481 100.100 5.870
202203 5.313 101.100 5.634
202206 4.859 101.800 5.117
202209 4.793 103.100 4.984
202212 4.948 104.100 5.095
202303 4.965 104.400 5.098
202306 4.969 105.200 5.063
202309 4.461 106.200 4.503
202312 4.757 106.800 4.775
202403 4.523 107.200 4.523

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Nxera Pharma Co  (STU:JSS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nxera Pharma Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=8.95/3.42
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nxera Pharma Co was 11.09. The lowest was 2.31. And the median was 4.58.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nxera Pharma Co Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (STU:JSS) Business Description

Industry
Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (STU:JSS) Headlines

No Headlines